Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | CTSS | P25774 | 2/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 3/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11455941 | 1.00 | CPB1 (0.54) | CPB1TSHRALDH1A1GAACTSB | |
| SCHEMBL11455046 | 0.97 | CPB1 (0.54) | CPB1TSHRALDH1A1GAACTSB | |
| SCHEMBL13223714 | 0.86 | SIGMAR1 (0.63) | CPB1TSHRALDH1A1GAACTSB | |
| SCHEMBL6612597 | 0.83 | EPHX1 (0.63) | CPB1TSHRALDH1A1GAACTSB | |
| SCHEMBL3563506 | 0.83 | CPB1 (0.57) | CPB1TSHRALDH1A1GAACTSB | |
| SCHEMBL22585843 | 0.83 | CPB1 (0.57) | CPB1TSHRALDH1A1GAACTSB | |
| SCHEMBL2848373 | 0.82 | ALDH1A1 (0.58) | CPB1TSHRALDH1A1GAACTSB | |
| SCHEMBL24515807 | 0.81 | CASP3 (0.62) | CPB1TSHRALDH1A1GAACTSB | |
| SCHEMBL5896898 | 0.81 | ALDH1A1 (0.57) | CPB1TSHRALDH1A1GAACTSB | |
| SCHEMBL4496128 | 0.81 | CASP3 (0.62) | CPB1TSHRALDH1A1GAACTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250009745-A1 | CDK INHIBITOR | SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) | 2025-01-09 | — | — | US | disclosed |
| EP-4289835-A1 | CDK INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022166793-A1 | CDK INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250009745-A1 | CDK INHIBITOR | CDK9, CDKL1, CDK6 | CPB1 3276/4885TSHR 3744/4885ALDH1A1 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.